Here are relevant reports on : route-optimization-market
-
Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030
The global veterinary monoclonal antibodies market, valued at US$1.52 billion in 2024, stood at US$1.70 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$3.06 billion by the end of the period. Opportunities in the market involve expanding therapeutic uses beyond dermatology and osteoarthritis, as well as developing new administration routes for monoclonal antibodies.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Companion Animal Pharmaceuticals Market by Animal Type (Dogs, Cats, Horses), Route of Administration (Oral, Injectable, Topical), Indication (Antibiotics, Parasiticides), Distribution Channel (Veterinary Hospitals & Clinics) & Region - Global Forecasts to 2027
The global companion animal pharmaceuticals market in terms of revenue was estimated to be worth $14.4 billion in 2022 and is poised to reach $19.6 billion by 2027, growing at a CAGR of 6.3% from 2022 to 2027. Major players operating in the market Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Elanco Animal Health Incorporated (US), Ceva Santé Animale (France), Virbac (France), Vetoquinol S.A. (France), Dechra Pharmaceuticals plc (UK) are some of the market players.
- Published: March 2023
- Price: $ 4950
- TOC Available:
-
Europe Pharmaceutical Drug Delivery Market By Route of Administration [Oral (Tablet, Capsule), Injector, Topical (Cream, Transdermal Patch), Transmucosal, Nasal], Application [Cancer, Diabetes], Care Setting [Hospital, Homecare]-Forecast to 2031
Europe Pharmaceutical Drug Delivery market, valued at US$501.6 million in 2025, stood at US$519.6 million in 2026 and is projected to advance at a resilient CAGR of 6.2% from 2026 to 2031, culminating in a forecasted valuation of US$703.2 million by the end of the period. The major trends in this market are self-administration, technology-driven drug delivery, sustainable drug delivery, and drug device combinations.
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
Hemophilia Treatment Market by Indication (Type A, Type B), Therapy (Replacement (Recombinant, Plasma Derived), Route of Administration, End User - Global Forecast to 2027
The global hemophilia treatment market is projected to reach USD ~15 billion by 2027 from USD 12 Billion in 2022, at a CAGR of 5% during the forecast period. The major players in the global hemophilia market are Bayer Healthcare (Germany), Octapharma AG (Switzerland), Novo Nordisk (Denmark), Kedrion (Italy), Pfizer Inc. (US), Biogen (US) among others.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Vitamin D Therapy Market by Route of administration (Oral, Parenteral), Age Group (Children, Adult, Senior Adult), Purchase Pattern (OTC, Prescription), Application (Osteoporosis, Rickets, Autoimmune Disorder, Skin Diseases) - Global Forecast to 2024
The vitamin D therapy market is projected to reach USD 3.3 billion by 2024 from USD 1.9 billion in 2019, at a CAGR of 11.6% during the forecast period. Growth in this market is largely driven by the growing awareness about vitamin D deficiency and the presence of a large target patient population. On the other hand, the fortification of foods is likely to challenge the growth of this market. Some of the major players in this market include Abbott (US), Sanofi (France), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Merck & Co., Inc. (US), Torrent Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Alkem Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), and Cadila Healthcare Ltd. (India).
- Published: April 2019
- Price: $ 4950
- TOC Available:
-
Stomach Cancer Treatment Market by Treatment, Type (Chemotherapy, Immunotherapy), Disease Indication (Gastric Cancer), Route of Administration, Drug Class (PD-1/PD-L1 inhibitors, HER2 antagonists), Distribution Channel - Global Forecast to 2027
The global stomach cancer treatment market is projected to reach USD 8 billion by 2027 from USD 4 Billion in 2022, at a CAGR of 14% during the forecast period
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)), Application (Joint Pain, Cancer), Animal (Companion and Livestock), End User (Hospital, Pharmacy) - Global Forecast to 2027
Veterinary pain management market growth is primed to transition from $1.8 billion in 2022 to $2.5 billion by 2027, showcasing a strong CAGR of 6.7%. Factors such as growth in companion animal adoption, the increasing number of veterinary practitioners and their rising income levels in developed economies, increasing consumption of meat & milk, the growing prevalence of animal disease causing pain and inflammation, and rising adoption of pet insurance with growing animal health expenditure are expected to drive the growth of this market.
- Published: September 2022
- Price: $ 4950
- TOC Available:
-
Veterinary API Market by API Type (Antimicrobials (Fluoroquinolones, Tetracyclines), Vaccines, Hormones, Antimicrobials, Anti-inflammatory, Hormones), Synthesis Type, Route of Administration, and Animal Type - Global Forecast to 2028
The global veterinary API market, valued at US$8.0 billion in 2022, stood at US$8.5 billion in 2023 and is projected to advance at a resilient CAGR of 6.9% from 2023 to 2028, culminating in a forecasted valuation of US$11.9 billion by the end of the period. The veterinary active pharmaceutical ingredient (API) market is growing due to various factors, including the increased occurrence of transboundary and zoonotic diseases, a rise in the global animal population and pet ownership, and the implementation of improved disease control and prevention measures.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
US Pharmaceutical Drug Delivery Market by Route of Administration [Oral (Tablet, Capsule), Injectable, Topical (Cream, Transdermal, Suppositories), Ocular, Nasal, Transmucosal, Implantable], Application (Cancer, Diabetes), Care Setting - Forecast to 2031
The US pharmaceutical drug delivery market is projected to reach USD 1.24 billion by 2031 from USD 0.94 billion in 2026, at a CAGR of 5.8% during the forecast period. Some of the prominent players in the US pharmaceutical drug delivery market include Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), F. Hoffmann-La Roche (Switzerland), Becton, Dickinson and Company (US), Merck & Co., Inc. (US), Amgen, Inc. (US), AbbVie Inc. (US), Gilead Sciences, Inc. (US), Eli Lilly and Company (US), Bristol-Myers Squibb (US), Biogen (US), Baxter International (US), West Pharmaceutical Services (US), Catalent Pharma Solutions (US), and Novartis (Switzerland).
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Pharmaceutical Drug Delivery Market by Route of Administration (Oral, Injectors (Auto Injectors), Implantable, Transmucosal, Nasal, Syringes), Application (Cancer, Diabetes), Care Setting (Hospital, Home Care) - Global Forecast to 2031
The Asia Pacific (APAC) pharmaceutical drug delivery market is projected to reach USD 687.9 million by 2031 from USD 479.7 million in 2026 at a CAGR of 7.5% during the forecast period. Some of the major players in the APAC pharmaceutical drug delivery market include Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Terumo Corporation (Japan), Becton, Dickinson and Company (US), Merck & Co., Inc. (US), B. Braun (Germany), Gerresheimer AG (Germany), Cipla (India), Eli Lilly and Company (US), Novartis (Switzerland), Biogen (US), Baxter International (US), West Pharmaceutical Services (US), Sun Pharmaceutical Industries (India), GlaxoSmithKline (UK).
- Published: February 2026
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
